Dr. Shawn Kile is a board-certified neurologist with expertise in treating cognitive disorders. He cares for patients with dementia, traumatic brain injury, autism, encephalopathy, and other neurocognitive illnesses. Dr. Kile has authored numerous publications and presented internationally on new approaches to managing Alzheimer’s disease, dementia, neurobehavioral disorders and traumatic brain injury. He is a Principal Investigator for physician-initiated trials supported by the Sutter Institute for Medical Research (SIMR) and phase 2-3 clinical studies assessing the efficacy of new therapies for Alzheimer’s disease and adult autism.
Sutter Health Research Enterprise
2800 L Street, Suite 500
Sacramento, CA, 95816
(916) 454-6850
simr@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Alzheimers (Alzheon ApolloE4)
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4)
Investigators: Shawn Kile MD, Nicklesh Thakur MD
Status: Active, Recruiting
GRADUATE Early Alzheimer's
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Investigator: Shawn Kile MD
Status: Active, Not Recruiting
New IDEAS
New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study
Investigators: David Eric Collins MD, Shawn Kile MD, Armen Moughamian M.D., Ph.D., Medical Director, Ray Dolby Brain Health Center
Status: Active, Recruiting
Publications
Brain regions showing increased activation by threat-related words in panic disorder.
Brain regions showing increased activation by threat-related words in panic disorder.
Neuropsychiatric update: neuroimaging schizophrenia.
Neuropsychiatric update: neuroimaging schizophrenia.
Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease
Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease
IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia
To determine the effect of intravenous immunoglobulin on brain atrophy and cognitive function in mild cognitive impairment due to Alzheimer's disease